Neoadjuvant Abemaciclib Active in HER2-Positive/HR-Negative Breast Cancer

A neoadjuvant regimen combining the CDK4/6 inhibitor abemaciclib with anastrozole induced a response rate of 54.7% in patients with HER2-positive/HR-negative early-stage breast cancer, according to findings from the phase II neoMONARCH trial presented at the 2016 San Antonio Breast Cancer Symposium.

click me